Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
DateTitle 
12/16/14Geron Announces Early HSR Clearance for Global Strategic Collaboration with JanssenPrinter Friendly Version
12/05/14Geron to Host Analyst and Investor Meeting on December 8Printer Friendly Version
12/04/14Geron Announces Publication of Preclinical Data on Imetelstat Activity in Acute Myelogenous LeukemiaPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$3.12
Change (%) Stock is Down 0.14 (4.29%)
Volume2,273,152
Data as of 12/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
  
Contact Information

Kevin Eng, Ph.D.
Tel: 650-473-7765
E-mail: investor@geron.com or media@geron.com



RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Close
Form content here please :)